The Uromigos

Episode 403: ADCs in Bladder Cancer. Part 2 from the Canary Islands

02 Apr 2025

Contributed by Lukas

Ignacio Duran continues his discussion with Brian and Tom regarding novel ADCS in bladder cancer

Episode 402: Uromigos en Espanol: Futuro del carcinoma de células renales

31 Mar 2025

Contributed by Lukas

Cristina Suárez analiza los próximos ensayos clínicos que podrían transformar el manejo del cáncer renal en los próximos años: nuevas combinaci...

Episode 401: ADCs in Bladder Cancer. Part 1 from the Canary Islands

29 Mar 2025

Contributed by Lukas

Ignacio Duran joins the show to discuss the landscape of established ADCs in urothelial cancer and challenges of drug development in this setting.

Episode 400: The Uromigos Score for Urothelial Cancer

28 Mar 2025

Contributed by Lukas

Live from the Canary Islands 'Big Idea' talk from Tom, we discuss the new Uromigos Score which ranks different treatment options in several ur...

Episode 399: A PD1/VEGF Bispecific in Lung Cancer - Lessons for GU Cancers?

24 Mar 2025

Contributed by Lukas

Dr. John Heymach from MD Andersons joins us to discuss a novel PD1/VEGF bispecific agent in lung cancer and if there are applicaitons in GU malignanci...

Episode 398: Reflections on the Felix Feng Symposium at ASCO GU

17 Mar 2025

Contributed by Lukas

Chuck Ryan joins us to discuss his interview with Felix and reflects on his keynote address at ASCO GU 2025.

Episode 397: APCCC Diagnostics Conference recap

10 Mar 2025

Contributed by Lukas

Silke Gillessen joins us to discuss the top areas of consensus and controversy from APCCC 2025

Episode 396: Uromigos Japan - 激論 @JSMO25

09 Mar 2025

Contributed by Lukas

尿路上皮癌と腎癌の臨床に影響を与えるエビデンスをどう解釈するか!?

Episode 395: Uromigos Japan: ASCO GU 2025のレビュー

03 Mar 2025

Contributed by Lukas

ASCOGU2025で発表された臨床試験の結果の解釈について忖度なしに議論しました！！

Episode 394: APCCC (Advanced Prostate Cancer Consensus Conference) Diagnostics 2025

01 Mar 2025

Contributed by Lukas

Tyler Seibert from UCSD joins the show live from Lugano to discuss meeting highlights and controversies (and his favorite run along the water..)

Episode 393: ASCO GU 2025 Review Podcast

26 Feb 2025

Contributed by Lukas

Silke joins Tom and Brian to discuss highlights form ASCO GU 2025

Episode 392: ASCO GU 2025 - HIF Inhibition with Casdatifan in Refractory RCC

15 Feb 2025

Contributed by Lukas

Toni Choueiri discusses the updated data from different cohorts of this novel HIF inhibitor.

Episode 391: ASCO GU 2025 - KIM-1 Data from Checkmate 214

15 Feb 2025

Contributed by Lukas

Vincent Xu discusses this emerging RCC biomarker and data from the Checkmate 214 trial

Episode 390: ASCO GU 2025 - Pembro-based Doublets in Refractory RCC and COSMIC-313 OS Update

15 Feb 2025

Contributed by Lukas

Laurence Albiges joins the show to discuss novel combos in refractory RCC and an update of the Ipi/Nivo/Cabo COSMIC OS data

Episode 388: ASCO GU 2025 - FGF3 Inhibition with LOXO-435 in Urothelial Cancer

15 Feb 2025

Contributed by Lukas

Gopa Iyer from MSKCC joins the show to discuss his initial results from this phase 2 trial.

Episode 387: ASCO GU 2025 -Neoadjuvant Disitamab Vedotin + Toripalimab in HER2+ MIBC: updated efficacy and safety results

14 Feb 2025

Contributed by Lukas

Xinan Sheng. M.D., Professor in the Department of Genitourinary Oncology at Peking University Cancer Hospital &institute in Beijing, China joins u...

Episode 389: ASCO GU 2025 - NIAGARA Pathologic CR Updates and Outcomes

14 Feb 2025

Contributed by Lukas

Matt Galsky joins the show to discuss pCR in NIAGARA and clinical implications.

Episode 386: ASCO GU 2025 - APRI Meta-analysis

13 Feb 2025

Contributed by Lukas

Tanya Dorff from City of Hope joins us to discuss clinical implications of these data and also comment on TALAPRO-2

Episode 385: ASCO GU 2025 - TALAPRO-2

13 Feb 2025

Contributed by Lukas

Neeraj Aggarwal joins Tom and Brian for an in-depth look at these important data

Episode 384: ASCO GU Preview

06 Feb 2025

Contributed by Lukas

Silke Gillessen joins Brian and Tom and they discuss what to look forward to in prostate, bladder and RCC at ASCO GU 2025.

Episode 383: A Neoantigen Vaccine Generates Anti-tumor Immunity in RCC

05 Feb 2025

Contributed by Lukas

David Braun joins the show to discuss his Nature paper on a personalized RCC vaccine

Episode 382: Uromigos Japan - TROPICs-04の考察

05 Feb 2025

Contributed by Lukas

残念ながらNegative StudyとなったTROPICs-04についてUromigos Japanの3人が忖度なしに、その原因や理由について考察をし...

Episode 381: Molecular heterogeneity in urothelial carcinoma and determinants of clinical benefit to PD-L1 blockade

27 Jan 2025

Contributed by Lukas

Romain Banchereau joins the show to discuss and debate this Cancer Cell paper on molecular subtypes in urothelial cancer and implications for checkpoi...

Episode 380: The Role of SBRT in RCC

13 Jan 2025

Contributed by Lukas

Shankar Siva joins the show to discuss the emerging role of stereotactic body radiotherapy (SBRT) in primary and metastatic RCC tumors.

Episode 379: Uromigos Japan: 2024年のGU Oncologyを振り返る

10 Jan 2025

Contributed by Lukas

3人による2024年のGU oncoloyのレビューを切れ味鋭く解説しています。乞うご期待！

Episode 378: 2025 Preview of Important GU Data

06 Jan 2025

Contributed by Lukas

Tanya Dorff from City of Hope joins Brian and Tom to review what to expect throughout 2025 and beyond in terms of clinically impactful data in prostat...

Episode 377: Prostate Cancer 2024 Highlights

23 Dec 2024

Contributed by Lukas

Silke Gilleson gives Tom and Brian 3 'gifts': Thomas Zilli (Radiation Oncology), Jochen Walz (Urology) and Ken Hermann (Nuclear Medicine) who discuss ...

Episode 376: Bladder Cancer 2024 Highlights

23 Dec 2024

Contributed by Lukas

Matt Galsky joins Brian and Tom to discuss the most impactful data in bladder cancer form the past year.

Episode 375: Renal Cancer 2024 Highlights

23 Dec 2024

Contributed by Lukas

David McDermott (and his dog, Finn) join the show to review the top data from 2024 in RCC

Episode 374: Mechanisms of HIF Resistance

18 Dec 2024

Contributed by Lukas

Jim Brugarolas joins to discuss his talk from IKCS 2024 and the board topic of resistance to HIF inhibitors.

Episode 373: KEYNOTE-564 Asian OSとANNARの解説

11 Dec 2024

Contributed by Lukas

JSCO2024で発表されたKEYNOTE-564東アジア人OSデータとANNAR biomarker studyの解説とディスカッションです

Episode 372: FDA Accelerated Approval Process

09 Dec 2024

Contributed by Lukas

Dan Suzman from FDA joins us to discuss the Accelerated Approval process, requirements, successes and challenges.

Episode 371: TROPICS-04 Results from ESMO Asia

07 Dec 2024

Contributed by Lukas

Jonathan Rosenberg joins Brian and Tom to discuss this important phase 3 trial and efficacy and toxicity signals.

Episode 370: Artificial Intelligence in Medical Oncology

02 Dec 2024

Contributed by Lukas

Jacob Kather joins Brian and Tom to discuss emerging AI applications in Oncology

Episode 369: Paper of the Month with Bishoy Faltas

25 Nov 2024

Contributed by Lukas

Bishoy joins us to discuss his work on extrachromosomal DNA in bladder cancer from his latest Nature publication

Episode 368: Radiomics in RCC: Live from IKCS

19 Nov 2024

Contributed by Lukas

Andrew Smith from St. Jude's joins us to discuss the emerging field of radiomics and shares his hopes and skepticism

Episode 367: Abiraterone vs AR inhibitors (Fanta vs Coke) in Prostate Cancer

11 Nov 2024

Contributed by Lukas

Chuck Ryan from MSKCC joins to talk about various aspects of AR inhibition in prostate cancer and relative benefits and risks.

Episode 366: ARPIs in Prostate Cancer - Are They Different?

04 Nov 2024

Contributed by Lukas

Chris Sweeney and Rob Jones join Brian and Tom to discuss the relative merits of different ARPIs in prostate cancer.

Episode 365: A Review of the Advanced Prostate Cancer Consensus Conference (APCCC)

28 Oct 2024

Contributed by Lukas

Episode 365: Silke Gillessen and Betrand Tombal join the show to discuss the APCCC meeting and recent publication.

Episode 364: 腎がんの最新の話題〜IO rechallengeと乳頭型腎がんの治療戦略〜

24 Oct 2024

Contributed by Lukas

腎がんの最新の話題〜IO rechallengeと乳頭型腎がんの治療戦略〜

Episode 363: 前立腺がんの最新の話題〜T cell directed therapyとradioligands〜

24 Oct 2024

Contributed by Lukas

前立腺がんの最新の話題〜T cell directed therapyとradioligands〜

Episode 362: 膀胱がんの最新の話題〜周術期薬物療法とADC〜

24 Oct 2024

Contributed by Lukas

膀胱がんの最新の話題〜周術期薬物療法とADC〜

Episode 361: The Role of Monotherapy AR Inhibition in Prostate Cancer

22 Oct 2024

Contributed by Lukas

Betrand Tombal joins Brian and Tom to discuss the historic and current data for AR inhibition with monotherapy with AR blockers.

Episode 360: The SUNRISE Program in Bladder Cancer

15 Oct 2024

Contributed by Lukas

Christopher Cutie from J&J joins the show to discuss the SUNRISE bladder program with the gemcitabine-eluting pretzel across several NMIBC and MIB...

Episode 359: #UromigosLive24 - IO after IO in RCC

09 Oct 2024

Contributed by Lukas

The RCC panel at Uromigos Live 2024 discusses and debates this topic.

Episode 358: Noticias del Dia 1 de Uromigos Live 2024 en Nashville

30 Sep 2024

Contributed by Lukas

En este podcast cubrimos los temas de cáncer urotelial discutidos por los Uromigos. El impacto del estudio NIAGARA en utiliar quimio más inmunot...

Episode 357: #UromigosLive24 - Peri-operative Therapy in Bladder Cancer

30 Sep 2024

Contributed by Lukas

Tom leads a panel of Shilpa Gupta, Andrea Apolo, Kala Sridhar and Petros Grivas to discuss and debate this timely topic.

Episode 356: #UromigosLive24 - Front-line Therapy in Papillary and Non-clear Cell RCC

28 Sep 2024

Contributed by Lukas

Brian moderates the panel that discusses and debates TKI, vs Ipi/Nivo vs IO/TKI

Episode 355: #UromigosLive24 - Radioligands in prostate cancer

28 Sep 2024

Contributed by Lukas

The Uromigos Live 2024 panel discusses recent radioligand data including PEACE-3

Episode 354: #UromigosLive24 - T cell directed therapy in prostate cancer

28 Sep 2024

Contributed by Lukas

Brian hosts a panel at Uromigos Live 2024 in Nashville with Michael Morris, Tanya Dorff and Karen Autio

Episode 353: #UromigosLive24 ADC session

28 Sep 2024

Contributed by Lukas

Tom moderates a live panel of Kala Sridhar, Shilpa Gupta, Andrea Apolo and Petros Grivas on the emerging ADC data in bladder cancer

Episode 352: ESMO 2024 - RCC and Bladder review

23 Sep 2024

Contributed by Lukas

Tom and Brian finish discussing ESMO 2024 highlights. Even without a guest Tom still interrupts a lot.

Episode 351: ESMO 2024 review part 1: prostate cancer

21 Sep 2024

Contributed by Lukas

Silke joins us to discuss ESMO 2024 highlights, then the birds start singing....

Episode 350: ESMO 2024 - NIAGARA

16 Sep 2024

Contributed by Lukas

Fresh of the Presidential session address, Tom discusses his data with Petros commenting.

Episode 349: ESMO 2024 - Uromigos Japan!!

16 Sep 2024

Contributed by Lukas

Uromigos Japan with Yuji, Hiroshi and Nobu is formed and discuss Hiroshi's ESMO data.

Episode 348: ESMO 2024 - UpFrontPSMA

15 Sep 2024

Contributed by Lukas

Arun Azad describes this randomised phase II study of sequential 177Lu-PSMA-617 and docetaxel vs. docetaxel in mHSPC

Episode 347: ESMO 2024 - DV + Pembro in Urothelial Cancer

15 Sep 2024

Contributed by Lukas

Matt Galsky describes his ESMO 2024 abstract of disitimab vedotiin + pembrlizumab in bladder cancer

Episode 346: ESMO 2024 - PEACE-3: Enza/Radium-223 vs Enza in mCRPC

14 Sep 2024

Contributed by Lukas

Silke Gillessen joins us to discuss her Presidential session from ESMO 2024

Episode 345: ESMO 2024 - SUNNIFORECAST: Ipi/Nivo vs SOC in Non-clear Cell RCC

14 Sep 2024

Contributed by Lukas

Lothar Bergmann describes this investigator-initiated trial of Ipi/Nivo vs SOC in Non-clear Cell RCC

Episode 344: ESMO 2024 - NKT2152, a HIF inhibitor in RCC

14 Sep 2024

Contributed by Lukas

Brad McGregor joins Brian and Tom to discuss a new HIF inhibitor, NKT2152, and preliminary data in RCC

Episode 343: ESMO 2024 - TiNivo-2 Trial

14 Sep 2024

Contributed by Lukas

Katy Beckermann discusses the TiNivo-2 study presented at ESMO 2024.

Episode 342: ESMO 2024 Preview with Silke Gillessen

03 Sep 2024

Contributed by Lukas

Silke joins Brian and Tom to discuss upcoming data in prostate, bladder and kidney cancer in Barcelona at ESMO 2024

Episode 341: Hormone Resistance in Prostate Cancer

27 Aug 2024

Contributed by Lukas

Nima Sharifi joins Brian and Tom to discuss mechanisms of resistance to hormone therapy in prostate cancer

Episode 340: Cancer Immunity Cycle Update

19 Aug 2024

Contributed by Lukas

Ira Mellman delves into the update of this classic paper and the components of an effective anti-tumor immune response.

Episode 339: Tres Uramigas analizan lineamientos de ESMO para GU

09 Aug 2024

Contributed by Lukas

María, Christina y Elena analizan los cambios recientes en las directrices de la ESMO en el cáncer de riñón, vejiga y próstata.

Episode 338: RCC: Debulking Nephrectomy, Adjuvant Therapy Future and More

06 Aug 2024

Contributed by Lukas

Naomi Haas joins Tom and Brian in New York City at the World GU Conference to discuss several RCC topics

Episode 337: Updated NCCN Guidelines in RCC

30 Jul 2024

Contributed by Lukas

Eric Jonasch, Co-Chair of the NCCN RCC Guidelines, gives insight into the process of guideline modification and discusses updates in adjuvant, front-l...

Episode 336: Which patients are not suitable for 1st line EVP in bladder cancer

24 Jul 2024

Contributed by Lukas

Jonathan Rosenberg and a surprise guest discuss comorbidities and treatment-related side effects.

Episode 335: Novel immune therapies for renal cancer

19 Jul 2024

Contributed by Lukas

David Braun divides immune therapies into four groups and describes how novel treatments and targets work. Tom and Brian are both excited and, at time...

Episodio 334 en español: Tres Uramigas ASCO 2024

11 Jul 2024

Contributed by Lukas

Escuche nuestro primer podcast sobre los aspectos más destacados de ASCO en cáncer de vejiga, riñón y próstata

Episode 333: The Uromigos Cup - The Netherlands

05 Jul 2024

Contributed by Lukas

Axel Bex, Christian Blank, Laura Mertens and Micheil Van der Heijden answer a range of relevant and sometimes irrelevant questions

Episode 332: The Uromigos Cup - Germany's Entry

26 Jun 2024

Contributed by Lukas

Viktor Gruenwald, Boris Hadaschik and Gunhild Von Amsberg answer questions around GU cancer and German football

Episode 331: AUA 2024 NMIBC Highlights

21 Jun 2024

Contributed by Lukas

Aditya Bagrodia describes three new drugs/studies in NMIBC.

Episode 330: ASCO 2024 Highlights

10 Jun 2024

Contributed by Lukas

Silke Gillessen joins Tom and Brian, who give their opinion on the data and new 'Take Home Message' format.

Episode 329: Japan in the Uromigos Cup qualifying round

07 Jun 2024

Contributed by Lukas

Nobuaki Matsubara, Hiroshi Kitamura and Yuji Miura battle through the sometimes ridiculous questions set by Tom and Brian.

Episode 328 ASCO24: Emergency podcast - what the NADINA trial means for preoperative GU cancer studies

05 Jun 2024

Contributed by Lukas

David McDermott discusses the adjuvant vs neoadjuvant immune therapy trial and its wider implications.

Episode 327 ASCO24: CM901 and EV302 Efficacy and QOL Updates

04 Jun 2024

Contributed by Lukas

Guru Sonpavde describes the efficacy of chemotherapy with nivolumab in lymph node only 1st line UC patients. Tom describes the QOL data for EV pembro....

Episode 326 ASCO24: KIM-1 in Renal Cancer

03 Jun 2024

Contributed by Lukas

Laurence Albiges discusses this circulating biomarker which may be predictive and prognostic.

Episode 325 ASCO24: KN426 and the CLEAR trial - tissue based biomarkers for kidney cancer

03 Jun 2024

Contributed by Lukas

Toni Choueiri and Brian describe similarities and differences in the biomarker findings of these two trials. Debate about the value and future of this...

Episode 324 ASCO24: SURE1 neoadjuvant sacituzumab govitecan in UC

02 Jun 2024

Contributed by Lukas

Andrea Necchi gives us the lowdown of efficacy and toxicity of this combination.

Episode 323 ASCO24: TDXD in Bladder Cancer

02 Jun 2024

Contributed by Lukas

Jonathan Rosenberg gets to grips with the data available for the bladder cohort from the TDXD Destiny pan-tumour cohort.

Episode 322 ASCO24: The role of ctDNA in the TheraP trial (LuPSMA vs cabazitaxel in CRPC)

02 Jun 2024

Contributed by Lukas

Alex Wyatt describes the predictive resistance of ctDNA fraction at baseline in predicting outcome.

Episode 321 ASCO24: CHAARTED-2 in prostate cancer - is the sequel as good as the original?

01 Jun 2024

Contributed by Lukas

Christos Kyriakopoulos describes the outcome of this study, where cabazitaxel with abiraterone as combined with abiraterone alone in docetaxel refract...

Episode 320: Team Canada's entry for the Uromigos Cup

25 May 2024

Contributed by Lukas

Danny Heng, Christian Kollmannsberger and Kala Sridhar answer questions in an attempt to get to Nashville and take on LA to win the Uromigos Cup.

Episode 319: ASCO 2024: A Preview of GU Data

19 May 2024

Contributed by Lukas

What to see at the ASCO 2024 Annual Meeting, with Silke Gillessen.

Episode 318: The Lancet Commission on prostate cancer: planning for a surge in cases

13 May 2024

Contributed by Lukas

Nick James discusses this paper, which covers broad issues in prostate cancer - including diagnosis and treatment with a focus on the future.

Episode 317: AUA 2024 Preview with the AUA Secretary

01 May 2024

Contributed by Lukas

David Penson discusses highlights for the upcoming meeting. He articulates his excitement around the NMIBC data.

Episode 316: APCCC 2024 Summary with Silke Gillessen

28 Apr 2024

Contributed by Lukas

Silke covers key aspects of the meeting, including surgery vs RT, genetic and somatic testing, PSMA imaging and 1st line triplet therapy.

Episode 315: APCCC 2024 Quickfire - Bone health, hot flashes and gynecomastia in prostate cancer

27 Apr 2024

Contributed by Lukas

Chris Sweeney is joined by Matt Smith, Anthony Joshua and Lisa Horvath to discuss the management of these complex issues in advanced prostate cancer. ...

Episode 314: APCCC 2024 Cardiovascular risks with hormone therapy in prostate cancer

27 Apr 2024

Contributed by Lukas

Thomas Suter and Chuck Ryan discuss identification and management of cardiovascular disease for patients starting therapy for prostate cancer.

Episode 313: APCCC 2024 Debate - Radiation therapy in advanced disease

26 Apr 2024

Contributed by Lukas

Thomas Zilli and Pierre Blanchard discuss this topic from Lugano.

Episode 312: APCCC 2024 Radiation therapy after surgery for prostate cancer

26 Apr 2024

Contributed by Lukas

Jason Efstathiou and Piet Ost discuss the data for and against this approach.

Episode 311: The Uromigos Paper of the Month - The POUT Trial

23 Apr 2024

Contributed by Lukas

Alison Birtle describes adjuvant chemotherapy in bladder cancer.

Episode 310: Dosing and duration of drugs from a cost perspective

17 Apr 2024

Contributed by Lukas

Daniel Goldstein describes his work on this issue.

Episode 309: EAU24 Checkmate 274 - OS for adjuvant nivolumab in bladder cancer

07 Apr 2024

Contributed by Lukas

In this second part, Matt Galsky describes the OS signal data. We also look into the future.

Episode 308: EAU24 IMVIGOR 011 - Outcome of ctDNA negative patients post-cystectomy

07 Apr 2024

Contributed by Lukas

Tom, Brian and Matt Galsky review the screening component of this study, presented at EAU24.

Episode 307: Bladder-Sparing Approaches Part 2

02 Apr 2024

Contributed by Lukas

Michiel Van der Heijden explores the role of radiotherapy and other neoadjuvant and other neoadjuvant combinations to prevent the need for surgery.

Episode 306: The Uromigos Paper of the Month - Chemo/Nivo as a bladder sparing approach in UC

28 Mar 2024

Contributed by Lukas

Matt Galsky describes his phase 2 study looking at gem/cis/nivo followed by nivo in responders. This potentially avoids cystectomy.

Episode 305: FDA and Oncology Clinical Trials

19 Mar 2024

Contributed by Lukas

FDA Deputy Oncology Director Dan Suzman described approaches to oncology trials. Tom asks 3 last questions which annoys Brian more than usual.

Episode 304: A PSMA CD3 Bispecific T-cell Engager in CRPC

11 Mar 2024

Contributed by Lukas

Tanya Dorff describes acapatamab, a prostate-specific membrane antigen (PSMA) CD3 bispecific engager.